[go: up one dir, main page]

WO2003016905A3 - Methodes - Google Patents

Methodes Download PDF

Info

Publication number
WO2003016905A3
WO2003016905A3 PCT/GB2002/003753 GB0203753W WO03016905A3 WO 2003016905 A3 WO2003016905 A3 WO 2003016905A3 GB 0203753 W GB0203753 W GB 0203753W WO 03016905 A3 WO03016905 A3 WO 03016905A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc
cell
histocompatibility complex
reactivity
determination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/003753
Other languages
English (en)
Other versions
WO2003016905A2 (fr
Inventor
Bent Karsten Jakobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Priority to AU2002319547A priority Critical patent/AU2002319547A1/en
Publication of WO2003016905A2 publication Critical patent/WO2003016905A2/fr
Publication of WO2003016905A3 publication Critical patent/WO2003016905A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode permettant de déterminer si un lymphocyte T réagit à un type déterminé de complexe majeur d'histocompatibilité (CMH). Dans le cadre de cette méthode, on met un lymphocyte T en contact avec une pluralité de molécules dudit type CMH, chaque molécule CMH étant complexée avec un antigène peptidique dont le rôle dans la liaison du récepteur de lymphocyte T avec le complexe antigène peptidique est réduit au minimum. On détermine ensuite si ladite pluralité de molécules CMH provoque une activation du lymphocyte T. Cette méthode permet d'évaluer l'activité allo-spécifique de lymphocytes T et peut être utilisée pour apparier des donneurs et des receveurs de greffons ainsi que pour surveiller des réponses allo-réactives à la suite d'une transplantation.
PCT/GB2002/003753 2001-08-16 2002-08-15 Methodes Ceased WO2003016905A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002319547A AU2002319547A1 (en) 2001-08-16 2002-08-15 Determination of t-cell/mayor histocompatibility complex (mhc) reactivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120042.7 2001-08-16
GB0120042A GB0120042D0 (en) 2001-08-16 2001-08-16 Methods

Publications (2)

Publication Number Publication Date
WO2003016905A2 WO2003016905A2 (fr) 2003-02-27
WO2003016905A3 true WO2003016905A3 (fr) 2003-10-30

Family

ID=9920550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003753 Ceased WO2003016905A2 (fr) 2001-08-16 2002-08-15 Methodes

Country Status (3)

Country Link
AU (1) AU2002319547A1 (fr)
GB (1) GB0120042D0 (fr)
WO (1) WO2003016905A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
US20090061478A1 (en) 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
US20110038881A1 (en) * 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2015188839A2 (fr) 2014-06-13 2015-12-17 Immudex Aps Détection générale et isolement de cellules spécifiques par liaison de molécules marquées
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2021087579A1 (fr) * 2019-11-08 2021-05-14 The University Of Sydney Compositions pour la détection de lymphocytes t alloréactifs
WO2024227447A1 (fr) * 2023-05-03 2024-11-07 Immunoracle Inc. Compositions et méthodes d'analyse d'un échantillon pour des cellules immunitaires spécifiques d'un antigène

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALTMAN J ET AL: "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 96, XP002135711, ISSN: 0036-8075 *
CLAAS FRANS H J: "Predictive parameters for in vivo alloreactivity.", TRANSPLANT IMMUNOLOGY. ENGLAND AUG 2002, vol. 10, no. 2-3, August 2002 (2002-08-01), pages 137 - 142, XP002249197, ISSN: 0966-3274 *
FALK K ET AL: "ALLELE-SPECIFIC PEPTIDE LIGAND MOTIFS OF HLA-C MOLECULES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, no. 24, 1 December 1993 (1993-12-01), pages 12005 - 12009, XP002068748, ISSN: 0027-8424 *
KIKUCHI AKIKO ET AL: "Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket.", IMMUNOGENETICS, vol. 43, no. 5, 1996, pages 268 - 276, XP002249196, ISSN: 0093-7711 *
KOZONO H ET AL: "PRODUCTION OF SOLUBLE MHC CLASS II PROTEINS WITH COVALENTLY BOUND SINGLE PEPTIDES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 369, no. 6476, 12 May 1994 (1994-05-12), pages 151 - 154, XP002018445, ISSN: 0028-0836 *
MUTIS TUNA ET AL: "Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.", NATURE MEDICINE., vol. 5, no. 7, July 1999 (1999-07-01), pages 839 - 842, XP002249195, ISSN: 1078-8956 *
REINSMOEN N L: "Cellular methods used to evaluate the immune response in transplantation.", TISSUE ANTIGENS, vol. 59, no. 4, August 2002 (2002-08-01), August, 2002, pages 241 - 250, XP002249198, ISSN: 0001-2815 *
UGER ET AL: "Creating CTL targets with epitope-linked beta 2-microglobulin constructs", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 4, 15 February 1998 (1998-02-15), pages 1598 - 1605, XP002115504, ISSN: 0022-1767 *
WHITE J ET AL: "Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, no. 5, 1999, pages 2671 - 2676, XP002959841, ISSN: 0022-1767 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
WO2003016905A2 (fr) 2003-02-27
GB0120042D0 (en) 2001-10-10
AU2002319547A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
WO2003016905A3 (fr) Methodes
Sylvester‐Hvid et al. Establishment of a quantitative ELISA capable of determining peptide–MHC class I interaction
Nikas et al. Uterine pinopodes in peri-implantation human endometrium. Clinical relevance.
AU2002322241A1 (en) Rapid diagnostic device, assay and multifunctional buffer
WO2003102018A3 (fr) Procedes d'analyse proteomique quantitative de glycoproteines
Sadegh-Nasseri et al. Exogenous antigens bind MHC class II first, and are processed by cathepsins later
CA2055430A1 (fr) Dosage de l'hemoglobine glycosylee
ATE433116T1 (de) Immunoassay zur bestimmung der freisetzung von neurotensin in die zirkulation
Appella et al. Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.
DK0674766T3 (da) Fremgangsmåde og apparat til identifikation af en for en mykobakterieinfektion ansvarlig mykobakterieart
ATE553846T1 (de) Reagensküvette
Long et al. Functional islet‐specific Treg can be generated from CD4+ CD25− T cells of healthy and type 1 diabetic subjects
Lei et al. Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines.
WO2005007677A3 (fr) Capture par affinite de peptides par micro-agencement et methodes associees
DK0746767T3 (da) Analysatorcuvette, fremgangsmåde og diagnostisk testkit til bestemmelse af analytter i helblodprøver
WO2006031883A3 (fr) Analyse d'interactions de liaison mhc-peptide
Blum et al. Antigen-presenting cells and the selection of immunodominant epitopes.
WO2001090153A3 (fr) Reactifs pour selection de cellules et modes d'utilisation
Mills et al. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity.
WO2008072275A3 (fr) Système télématique permettant d'utiliser des bandes de réactif de diagnostic et procédé pour acquérir des données d'étalonnage
de la Hoz Caballer et al. Chronic urticaria and Helicobacter pylori.
WO2005012509A3 (fr) Procede immunotherapeutique pour traiter les tumeurs
DK1386160T3 (da) Fremgangsmåde til påvisning af blodcelle-antigener og antistoffer rettet mod disse
NO960149L (no) Testanordning
WO2004037160A3 (fr) Test in vitro permettant d'etudier un compose prevoyant les parametres pharmacologiques et/ou pharmacocinetiques et/ou pharmacodynamiques d'un compose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP